ClinicalTrials.Veeva

Menu
T

The Headache Center | Headache Neurology Research Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Atogepant
Eptinezumab
quinidine
Dextromethorphan
Ubrogepant
AMG334

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 16 total trials

A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only
Migraine
Drug: Ubrogepant

Trial sponsors

Allergan logo
Theranica logo
AbbVie logo
Lundbeck logo
Amgen logo
E
Mayo Clinic logo
C

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems